TD Cowen Maintains Buy on Palvella Therapeutics, Raises Price Target to $133

Benzinga · 1d ago
TD Cowen analyst Ritu Baral maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $97 to $133.